Thermo Fisher Scientific Inc. (NYSE:TMO – Get Free Report) CEO Marc Casper sold 4,608 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $586.12, for a total transaction of $2,700,840.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Thermo Fisher Scientific Stock Performance
Shares of Thermo Fisher Scientific stock traded up $4.68 during mid-day trading on Monday, hitting $598.68. 1,711,604 shares of the stock were exchanged, compared to its average volume of 2,319,938. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The company has a 50-day simple moving average of $517.63 and a 200 day simple moving average of $509.85. The company has a market capitalization of $221.36 billion, a P/E ratio of 32.20, a P/E/G ratio of 2.42 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the company posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.
Thermo Fisher Scientific Dividend Announcement
Institutional Investors Weigh In On Thermo Fisher Scientific
Several large investors have recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its position in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the period. Darwin Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $170,000. Raymond James Financial Inc. boosted its holdings in Thermo Fisher Scientific by 7.4% in the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after buying an additional 53,542 shares during the period. Finally, California State Teachers Retirement System grew its stake in Thermo Fisher Scientific by 0.4% in the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after buying an additional 2,262 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on TMO. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Barclays lifted their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Jefferies Financial Group restated a “buy” rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Finally, Piper Sandler lifted their price target on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a report on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $619.41.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Read More
- Five stocks we like better than Thermo Fisher Scientific
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
-inc-logo-1200x675.jpg){kind=logo}
